.: ORİJİNAL ARAŞTIRMA
The Effects of COVID-19 on Psoriasis Patients Using Biologic Treatment: Two-Center Retrospective Study
Biyolojik Tedavi Kullanan Psöriyazis Hastalarına COVID-19'un Etkileri: İki Merkezli Retrospektif Çalışma
Turkiye Klinikleri J Dermatol. 2022;32(1):22-8
doi: 10.5336/dermato.2021-86216
Makale Dili: EN
Tam Metin
ABSTRACT
Objective: The aim of our study is to evaluate the status of continuation of treatment of our patients who received biologic treatment during the pandemic and how they were affected by coronavirus disease-2019 (COVID-19). Material and Methods: The clinical processes of patients with moderate-severe plaque psoriasis who were treated with biologics between March 2020 and February 2021 were evaluated. Results: Thirty-three (21.2%) of our 156 psoriasis patients who received biologic therapy stopped treatment at the beginning of the pandemic. Fourteen of the 123 patients who were continuing the treatment were positive for COVID-19. One of the 33 psoriasis patients who stopped biologic treatment was positive for COVID-19. There was no statistical difference between those who continued with biologic treatment and those who did not in the rates of positivity for COVID19 after contact with a COVID-19 positive person, and frequency of severe symptoms (p=0.607, p=1.00, respectively). In terms of the difference between the mean of Psoriasis Area Severity Index (PASI) scores at the onset of the pandemic and the mean of PASI scores at the 12th month, there was no statistical difference between those who were positive for COVID-19 and those who did not (p=0.782). Conclusion: We have observed that the treatment with biologic agents in psoriasis patients does not increase the COVID-19 transmission risk, does not cause severe disease, and does not increase the hospitalization rate and mortality rate.
Keywords: COVID-19; biological therapy; psoriasis; Psoriasis Area Severity Index
Objective: The aim of our study is to evaluate the status of continuation of treatment of our patients who received biologic treatment during the pandemic and how they were affected by coronavirus disease-2019 (COVID-19). Material and Methods: The clinical processes of patients with moderate-severe plaque psoriasis who were treated with biologics between March 2020 and February 2021 were evaluated. Results: Thirty-three (21.2%) of our 156 psoriasis patients who received biologic therapy stopped treatment at the beginning of the pandemic. Fourteen of the 123 patients who were continuing the treatment were positive for COVID-19. One of the 33 psoriasis patients who stopped biologic treatment was positive for COVID-19. There was no statistical difference between those who continued with biologic treatment and those who did not in the rates of positivity for COVID19 after contact with a COVID-19 positive person, and frequency of severe symptoms (p=0.607, p=1.00, respectively). In terms of the difference between the mean of Psoriasis Area Severity Index (PASI) scores at the onset of the pandemic and the mean of PASI scores at the 12th month, there was no statistical difference between those who were positive for COVID-19 and those who did not (p=0.782). Conclusion: We have observed that the treatment with biologic agents in psoriasis patients does not increase the COVID-19 transmission risk, does not cause severe disease, and does not increase the hospitalization rate and mortality rate.
Keywords: COVID-19; biological therapy; psoriasis; Psoriasis Area Severity Index
ÖZET
Amaç: Çalışmamızın amacı, pandemi döneminde biyolojik tedavi alan hastalarımızın tedavisine devam etme durumunu ve koronavirüs hastalığı-2019'dan [coronavirus disease-2019 (COVID-19)] nasıl etkilendiklerini değerlendirmektir. Gereç ve Yöntemler: Orta-şiddetli plak psöriyazisli biyolojik tedavi kullanan hastaların Mart 2020-Şubat 2021 tarihleri arasındaki klinik süreçleri değerlendirildi. Bulgular: Biyolojik tedavi alan 156 psöriyazis hastamızın 33'ü (%21,2) pandeminin başlamasıyla tedaviyi bıraktı. Tedaviye devam eden 123 hastanın 14'ü COVID-19'a yakalandı. Biyolojik tedaviyi bırakan 33 psöriyazis hastasından biri COVID-19'a yakalandı. Biyolojik tedaviye devam edenler ile devam etmeyenler arasında COVID-19 pozitif bir kişiyle temas sonrası COVID-19'a yakalanma oranları ve şiddetli semptom görülme sıklığı arasında istatistiksel fark yoktu (sırasıyla p=0,607, p=1,00). Pandemi başlangıcındaki ortalama Psöriazis Alan Şiddet İndeksi [Psoriasis Area Severity Index (PASI)] skoru ile 12. aydaki ortalama PASI skoru arasındaki fark açısından COVID-19 pozitif olanlar ile olmayanlar arasında istatistiksel bir fark yoktu (p=0,782). Sonuç: Psöriyazis hastalarında biyolojik tedavi kullanımının COVID-19 bulaşma riskini artırmadığını, ağır hastalığa neden olmadığını, hastaneye yatış ve ölüm oranını artırmadığını gözlemledik.
Anahtar Kelimeler: COVID-19; biyolojik tedavi; psöriyazis; Psöriazis Alan Şiddet İndeksi
Amaç: Çalışmamızın amacı, pandemi döneminde biyolojik tedavi alan hastalarımızın tedavisine devam etme durumunu ve koronavirüs hastalığı-2019'dan [coronavirus disease-2019 (COVID-19)] nasıl etkilendiklerini değerlendirmektir. Gereç ve Yöntemler: Orta-şiddetli plak psöriyazisli biyolojik tedavi kullanan hastaların Mart 2020-Şubat 2021 tarihleri arasındaki klinik süreçleri değerlendirildi. Bulgular: Biyolojik tedavi alan 156 psöriyazis hastamızın 33'ü (%21,2) pandeminin başlamasıyla tedaviyi bıraktı. Tedaviye devam eden 123 hastanın 14'ü COVID-19'a yakalandı. Biyolojik tedaviyi bırakan 33 psöriyazis hastasından biri COVID-19'a yakalandı. Biyolojik tedaviye devam edenler ile devam etmeyenler arasında COVID-19 pozitif bir kişiyle temas sonrası COVID-19'a yakalanma oranları ve şiddetli semptom görülme sıklığı arasında istatistiksel fark yoktu (sırasıyla p=0,607, p=1,00). Pandemi başlangıcındaki ortalama Psöriazis Alan Şiddet İndeksi [Psoriasis Area Severity Index (PASI)] skoru ile 12. aydaki ortalama PASI skoru arasındaki fark açısından COVID-19 pozitif olanlar ile olmayanlar arasında istatistiksel bir fark yoktu (p=0,782). Sonuç: Psöriyazis hastalarında biyolojik tedavi kullanımının COVID-19 bulaşma riskini artırmadığını, ağır hastalığa neden olmadığını, hastaneye yatış ve ölüm oranını artırmadığını gözlemledik.
Anahtar Kelimeler: COVID-19; biyolojik tedavi; psöriyazis; Psöriazis Alan Şiddet İndeksi
REFERANSLAR:
- WHO announces COVID-19 outbreak a pandemic. 2020. Cited: Mar 12, 2020. [Link]
- Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, et al. Covid-19 in immune-mediated inflammatory diseases - case series from New York. N Engl J Med. 2020;383(1):85-8. [Crossref] [PubMed] [PMC]
- Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020;82(5):1217-8. [Crossref] [PubMed] [PMC]
- Liu Y, Zhang C, Huang F, Yang Y, Wang F, Yuan J, et al. Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury. Natl Sci Rev. 2020;7(6):1003-11. [Crossref] [PubMed] [PMC]
- Russell B, Moss C, George G, Santaolalla A, Cope A, Papa S, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020;14:1022. [Crossref] [PubMed] [PMC]
- Feldmann M, Maini RN, Woody JN, Holgate ST, Winter G, Rowland M, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020;395(10234):1407-9. [Crossref] [PubMed] [PMC]
- Wang Q, Luo Y, Lv C, Zheng X, Zhu W, Chen X, et al. Nonadherence to treatment and patient-reported outcomes of psoriasis during the COVID-19 epidemic: a web-based survey. Patient Prefer Adherence. 2020;14:1403-9. [Crossref] [PubMed] [PMC]
- Rob F, Hugo J, Tivadar S, Boháč P, Gkalpakiotis S, Vargová N, et al. Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: a multicenter study in the Czech Republic. J Eur Acad Dermatol Venereol. 2020;34(11):e682-e4. [Crossref] [PubMed] [PMC]
- Georgakopoulos JR, Yeung J. Rate of patient-driven biologic treatment discontinuation during the COVID-19 pandemic in 2 academic hospital clinics at the University of Toronto. J Cutan Med Surg. 2020;24(4):424-5. [Crossref] [PubMed]
- Kara Polat A, Oguz Topal I, Karadag AS, Aksoy H, Koku Aksu AE, Ozkur E, et al. The impact of COVID-19 in patients with psoriasis: A multicenter study in Istanbul. Dermatol Ther. 2021;34(1):e14691. [Crossref] [PubMed] [PMC]
- Oguz Topal I, Kara Polat A, Zindancı İ, Kıvanç Altunay İ, Akbulut TÖ, Arıkan EE, et al. Adherence to systemic therapy in patients with psoriasis during the COVID-19 pandemic: A multicenter study. J Cosmet Dermatol. 2022;21(1):39-47. [Crossref] [PubMed] [PMC]
- Yiu ZZN, Parisi R, Lunt M, Warren RB, Griffiths CEM, Langan SM, et al. Risk of hospitalization and death due to infection in people with psoriasis: a population-based cohort study using the Clinical Practice Research Datalink. Br J Dermatol. 2021;184(1):78-86. [Crossref] [PubMed]
- Seirafianpour F, Sodagar S, Pour Mohammad A, Panahi P, Mozafarpoor S, Almasi S, et al. Cutaneous manifestations and considerations in COVID-19 pandemic: a systematic review. Dermatol Ther. 2020;33(6):e13986. [Crossref] [PubMed] [PMC]
- Brazzelli V, Isoletta E, Barak O, Barruscotti S, Vassallo C, Giorgini C, et al. Does therapy with biological drugs influence COVID-19 infection? Observational monocentric prevalence study on the clinical and epidemiological data of psoriatic patients treated with biological drugs or with topical drugs alone. Dermatol Ther. 2020;33(6):e14516. [Crossref] [PubMed]
- Camela E, Fabbrocini G, Cinelli E, Lauro W, Megna M. Biologic therapies, psoriasis, and COVID-19: our experience at the psoriasis unit of the University of Naples Federico II. dermatology. 2021;237(1):13-4. [Crossref] [PubMed] [PMC]
- Megna M, Ruggiero A, Marasca C, Fabbrocini G. Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears. J Dermatolog Treat. 2020;31(4):328-9. [Crossref] [PubMed]
- Mahil SK, Dand N, Mason KJ, Yiu ZZN, Tsakok T, Meynell F, et al; PsoProtect study group. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2021;147(1):60-71. [PubMed] [PMC]
- Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020;11(1):6317. [Crossref] [PubMed] [PMC]
- Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A. The effect of smoking on COVID-19 severity: a systematic review and meta-analysis. J Med Virol. 2021;93(2):1045-56. [Crossref] [PubMed] [PMC]
- Mantovani A, Byrne CD, Zheng MH, Targher G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2020;30(8):1236-48. [Crossref] [PubMed] [PMC]
- Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021;93(3):1449-58. [Crossref] [PubMed] [PMC]
- Ebrahimi A, Sayad B, Rahimi Z. COVID-19 and psoriasis: biologic treatment and challenges. J Dermatolog Treat. 2020:1-5. [Crossref] [PubMed]
- Mroz M, Mućka S, Miodońska M, Ziolkowska D, Hadas E, Bożek A. Influence of SARS-CoV-2 virus infection on the course of psoriasis during treatment with biological drugs. Medicina (Kaunas). 2021;57(9):881. [Crossref] [PubMed] [PMC]
.: İşlem Listesi